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Background: Esophageal stenosis following endoscopic submucosal dissection (ESD) is a serious adverse event that
makes subsequent management more difficult.
Methods: This parallel, randomized, controlled, open-label study was designed to examine whether local steroid
injection is an effective prophylactic treatment for esophageal stenoses following extensive ESD. This single center trial
was conducted at the Keiyukai Hospital, a tertiary care center for gastrointestinal disease in Japan [University Hospital
Medical Network Clinical Trial Registry (UMIN-CTR) on 15 September 2011 (UMIN000006327)]. Thirty-two patients with
mucosal defects involving ≥75% of the esophageal circumference were randomized to receive a single dose of
triamcinolone acetonide injections (n = 16) or be treated conventionally (n = 16). The primary outcome was the
frequency of stricture requiring endoscopic dilatation; the surrogate primary endpoint was the number of dilatation
sessions needed. Secondary outcomes included adverse event rates, the minimum diameter of the stenotic area and
the duration of the course of dilatation treatments.
Results: The frequency of stricture was not significantly different between the groups because of insufficient statistical
power, but the number of dilatation sessions required was significantly less in the steroid group (6.1 sessions
[95% confidence interval, CI 2.8–9.4] versus 12.5 [95% CI 7.1–17.9] sessions in the control group; P = 0.04). The
perforation rate was similar in both groups. The minimum diameter of stenotic lumens was significantly greater
in the treatment group than controls (11.0 mm versus 7.1 mm, respectively; P = 0.01). The perforation rate was not
significantly different between the groups (1.0% versus 0.5% in the treatment and control group, respectively).
Steroid injection was effective in cases of mucosal defects encompassing the entire esophageal circumference.
Conclusions: Prophylactic endoscopic steroid injection appears to be a safe means of relieving the severity of
esophageal stenoses following extensive ESD.
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In Japan, endoscopic submucosal dissection (ESD) is widely
accepted as a standard treatment for early esophageal squa-
mous cell carcinomas without documented metastasis. The
ESD technique has been shown to reduce the risk of local
recurrence, and perforations arising as a consequence of
treatment are generally well tolerated [1]. As ESD can
excise larger lesions than endoscopic mucosal resection,
it is becoming increasingly popular, but esophageal sten-
osis after removal of large lesions by ESD is a major con-
cern. Mucosal defects extending over three-quarters of the
circumference of the esophagus after endoscopic resection
are closely associated with the subsequent development of
esophageal stenosis [2], which can cause dysphagia and
impair quality of life.
Patients with esophageal stenosis are frequently treated
by endoscopic dilatation therapy. The risk of perforation
complicating the procedure increases with the number of
therapeutic sessions [3]. It is important to identify ways of
preventing esophageal stenosis after ESD, and minimizing
the complications associated with treatment when it does
arise. Treatment options for esophageal stenosis include
mechanical dilatation with a bougie or balloon, stent
placement and autologous keratinocyte implantation
[4]. Dilatation therapies may, however, have a higher in-
cidence of adverse events and recurrence rates than previ-
ously thought [5-7]. Therefore, simple, safe, reliable and
inexpensive approaches are needed to cope with iatrogenic
esophageal stenoses.
Systemic [8] or local [9,10] administration of steroids is
reported to be an effective means of addressing esophageal
stenosis after ESD, as well as for peptic stenosis [11-13].
Although systemic steroids should be avoided in patients
with diabetes mellitus or hypertension, locally adminis-
tered steroids appear to be safe in the vast majority of
patients [10]. Locally administered steroids have minimal
systemic effects owing to the small dose administered and
short duration of exposure [10]. Previous retrospective
and controlled prospective studies of endoscopic ster-
oid injection therapy have found that the incidence of
esophageal stenosis following ESD in patients treated with
steroid was 10–19%, compared with 66–75% in untreated
control groups. In addition, steroid injection therapy
significantly reduced the number of required dilatation
sessions.
To our knowledge, no randomized studies to date have
analyzed the potential preventative benefits of endoscopic
steroid injection therapy, or whether it is safe and effect-
ive, for stenosis caused by a mucosal defect involving the
entire circumference of the esophagus after ESD. We
undertook a prospective, randomized controlled trial to
analyze the prophylactic effects of endoscopic steroid
injection therapy for esophageal stenoses complicating
extensive ESD.Methods
This randomized, controlled, open-label study was per-
formed at Keiyukai Sapporo Hospital, Japan. All participants
gave their written informed consent, based on the Helsinki
Declaration (1964, 1975, amended in 1983, 2003 and 2008)
of the World Medical Association, and the Ethics Commit-
tee of Keiyukai Sapporo Hospital approved the study proto-
col. The study was designed according to the CONSORT
guidelines and was registered with the University Hospital
Medical Network Clinical Trial Registry (UMIN-CTR) on
15 September 2011 (UMIN000006327).
Study groups
Patients who had undergone ESD to treat histologically
confirmed early squamous cell carcinoma of the esopha-
gus from February 2010 to October 2011 and who were
expected to have a mucosal defect encompassing ≥75%
of the circumference of the esophageal mucosa after ESD
were eligible for the study. Patients who received additional
adjuvant treatments, such as surgery or chemoradiation
therapy, and patients who were not regularly or adequately
followed-up were excluded. Depth of tumor invasion was
determined based on the findings of endoscopy and/or
endoscopic ultrasonography. Mucosal to slightly invasive
submucosal cancers (of invasion less than 200 μm in
depth) were regarded as indications for ESD. Removal
of a carcinoma involving two-thirds of the circumfer-
ence of the esophagus by ESD was expected to result in
a mucosal defect spanning more than three-quarters of
the circumference. Patients enrolled in the study were
randomized to receive steroid injection therapy or to be
treated conventionally. Randomization was computer-
generated with concealed allocation using sequentially
numbered containers. Data were collated at Sapporo
Medical University and independently analyzed by one
author (Y.A.). The baseline demographic and clinical char-
acteristics of the study population were compared on the
basis of age, sex, tumor location, proportion of the esopha-
geal circumference involved, number of multiple Lugol
voiding lesions [14], clinical T factor [15] and follow-up
period (Table 1). All ESD procedures (Figure 1A–C) were
performed as described in our previous report [1]. The
characteristics of the ESD procedures undertaken in the
treatment and control groups were compared on the basis
of the size of the tumor and resected specimen, depth of
invasion, operation time, pathological margin, mucosal
circumferential defect and peri-procedural perforation
(Table 2).
Protocol for endoscopic steroid injection and dilatation
therapy
As previously described [9,10], patients who did not de-
velop immediate complications, such as perforation or
bleeding, during the ESD procedure and who had been
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ally injected with triamcinolone acetonide (Kenacort-A®,
40 mg/ml, Bristol-Myers Squibb, Anagni, Italy) immedi-
ately after the procedure. Triamcinolone was diluted
with 0.9% NaCl to a final concentration of 10 mg/ml,
then 0.5 ml aliquots were injected at the base of the
artificial ulcer using a 25-gauge, 3 mm needle (TOP
Corporation, Tokyo, Japan; Figure 1D). Injection com-
menced at the distal edge of the ulcer base and was
repeated evenly at points 10 mm apart towards the
proximal edge, taking care to avoid injuring the mus-
cularis propria.
Esophagogastroduodenoscopy (EGD) was performed to
assess for stenosis, bleeding or perforation at the injected
sites 6 days after treatment (Figure 2). Barium contrast
esophagography was performed in patients who com-
plained of dysphagia, or 4 weeks after the last EGD if
patients were asymptomatic, to quantitatively assess sten-
osis (Figure 3). Esophageal stenosis was defined as an
esophageal diameter <11 mm, rather than the inability
to pass the gastroscope (which had a diameter of 9.8–
11.0 mm) or inability to achieve or maintain a diameter
of 14 mm despite dilatation every 2–4 weeks [5,16].
The luminal diameter was estimated by measurement
of the minimum diameter of the stricture on esophago-
graphy (for examples, see Figures 3 and 4). Dilatation
therapy was performed every 1–4 weeks as previously
described [3]. Briefly, dilatation was performed in the
outpatient department under fluoroscopic guidance using a
Maloney (Medovations, Milwaukee, WI) or Savary (Wilson
Cook Medical, Winston-Salem, NC) wire-guided dila-
tor [17]. Dilatation therapy was considered successful
when patients did not report any symptoms of dysphagiawithout having needed dilatation in the previous 4 weeks
(Figure 5).
Statistical analysis
The incidence of esophageal stenoses and the frequency
of dilatation sessions required were compared in the treat-
ment and control groups. Independent t tests were used
to compare age, resection size and procedure time. The
primary study endpoint was the frequency of stricture re-
quiring endoscopic dilatation for esophageal stenosis after
ESD. A surrogate primary endpoint, the number of dilata-
tion sessions required, was subsequently included in the
analysis because the primary endpoint did not reach
statistical significance. Secondary endpoints included
the frequency of complications that occurred as a con-
sequence of either local steroid injection or endoscopic
dilatation, the minimum diameter of the stenotic area
and the duration of the course of dilatation treatments
(Tables 3 and 4). The number of patients to be enrolled
was determined in advance using a power calculation
for two-sample proportions test based on expected
bougienage rates of 13% with and 60% without steroid
injection, informed by previous reports of esophageal pep-
tic stricture rates [13], with an α error of 0.05 (two-tailed)
and a β error of 0.2. Consequently, the number of patients
required in each group was calculated as 16 using R statis-
tical software [18]. Post hoc analysis was also undertaken
to compare the group of patients with whole circumferen-
tial mucosal defects (WCMD) with the group of those
with lesions that involved less than the whole circumfer-
ence (non-WCMD, NWCMD; Table 4), and a further
analysis of the characteristics of patients with WCMDs
was made (Table 5). All other statistical analyses were
performed using IBM SPSS Statistics version 21 (IBM
Japan, Tokyo, Japan). Chi-square tests were used to com-
pare nominal and ordinal variables, with the exact P value
based on Pearson’s statistics or the Monte Carlo method
applied as appropriate. We used t tests or Mann–Whitney
tests for ratio scale variables, and for all tests a two-tailed
P value of <0.05 was considered statistically significant.
Results
Recruitment began in February 2010 and the last follow-
up was in October 2011. The trial ended because data
were considered complete. During the study period, 209
patients with 256 lesions underwent ESD in our hospital,
42 of whom (20.1%) were enrolled in the study because
they were expected to have mucosal defects extending
over three-quarters of the esophageal circumference due
to the ESD. Since one of these 42 patients declined to
participate, in total 41 were enrolled and randomized. 21
were allocated to the injection (treatment) group whereas
20 were allocated to the non-injection (control) group.
However, after ESD, nine patients were excluded from the
Figure 1 Typical endoscopic views of the esophagus in a patient in the injection group. a. A superficial esophageal carcinoma in the middle
esophagus. The entire circumference of the lesion was marked out by electrocautery using a needle-knife at least 1 mm from the tumor
border, confirmed by a Lugol-unstained region. b. This tumor encompasses half the circumference of the esophagus, as seen in the center of
the lesion. c. The artificial ulcer encompassed the entire circumference after ESD. d. Injection of triamcinolone into the ulcer (white arrow).
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received additional therapy. Of the latter eight patients,
seven had submucosal invasion that exceeded 200 μm and
one had lymphatic invasion despite a depth of invasion
of only 180 μm. Ultimately, 16 patients were allocated
to each group (Figure 6).
Comparison of treatment and control groups
Patients’ baseline demographic and clinical characteristics
(Table 1) and those of the ESD procedures (Table 2) were
not significantly different between the groups. No patient
experienced perforation caused by steroid injection or any
other side effects of steroids. The frequency of stricture
was not significantly different between the treatment (n =
10, 62.5%) and control (n = 14, 87.5%) groups (P = 0.22,
Table 3). The mean number of sessions of dilatation ther-
apy was significantly lower in the treatment than in the
control group (6.1 sessions [95% confidence interval, CI
2.8–9.4 sessions] versus 12.5 sessions [95% CI 7.1–17.9sessions]; P = 0.04). The perforation rate caused by dila-
tation procedures was 1.0% (one out of 97 sessions) in
the steroid injection group and 0.5% (one out of 200
sessions) in the control group. The mean minimum diam-
eter of stenotic lumens just before dilatation therapy was
greater in the treatment group than controls (11.0 mm
[95% CI 8.5–13.4 mm] versus 7.1 mm [95% CI 5.5–8.6],
P = 0.01; Figure 4). The duration of dilatation therapy
was 3.5 months in the treatment group and 6.1 months
in the control group, but the difference was not statisti-
cally significant (P = 0.11, Table 3).
Post hoc comparison between patients with whole and
non-whole circumferential mucosal defects
There were no significant differences in the baseline demo-
graphic, clinical or ESD characteristics of the 10 patients
with WCMDs compared with the remaining 22 with
NWCMDs (data not shown). The incidence of stric-
ture was significantly more frequent (100% versus 63.6%,
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Pathological margin free, n (%) 15 (93.8) 15 (93.8) 0.99
Mucosal defect of circumference,
n (<75% / ≥75%)
11/5 11/5 0.99
Perforation by ESD, n (%) 0/16 (0) 0/16 (0) 0.55
Abbreviations: m1, carcinoma in situ; m2, intramucosal invasive carcinoma limited
to the lamina propria mucosa; m3, carcinoma limited to the muscularis mucosa;
sm2, submucosal invasion between sm1 (slight invasion less than 200 μm in
depth) and sm3 (massive invasion); SD, standard deviation; ESD, endoscopic
submucosal dissection.
*Three patients with sm2 invasion had relative contraindications for surgical
intervention for one or more of the following reasons: age considerations (the
patients were 76, 79 and 89 years old), serious medical conditions (cerebral
vascular disease, multiple primary cancers, low performance status), and/or
patients’ decisions to decline surgery. A treatment plan for these patients was
carefully chosen under full informed consent.
Takahashi et al. BMC Gastroenterology  (2015) 15:1 Page 5 of 10P = 0.035) and the mean number of dilatation therapy
sessions required was significantly more (16.3 versus
6.1 sessions, P = 0.013) in those with WCMD lesions.
The perforation rate caused by dilatation procedures
was similar: 0.6% (one out of 163 sessions) in the
WCMD group compared with 0.7% (one out of 134
sessions) in the NWCMD group. The mean minimum
diameter of stenotic lumens immediately beforeFigure 2 Endoscopic view 6 days after endoscopic submucosal dissectio
The right picture (a) is a magnification of the left picture (b).dilatation therapy was smaller in the WCMD group (7.2
versus 9.9 mm in the NWCMD group) but the difference
was not significant (P = 0.10). The mean duration of dila-
tation therapy was significantly longer (8.1 versus
3.3 months, P = 0.047) in the WCMD group (Table 4).
Subgroup analysis of the whole circumference mucosal
defect group
Comparisons of patients in the WCMD subgroup treated
with steroid (n = 5) and those treated conventionally (n = 5)
revealed no significant differences in baseline demographic,
clinical or ESD characteristics (data not shown). The only
treatment-related factor that differed significantly between
the groups was the mean number of dilatation therapy
sessions required, which was lower in those treated with
steroids compared with controls (10.4 sessions [95% CI
6.0–14.8 sessions] versus 22.2 sessions [95% CI 9.0–35.4
sessions], respectively, P <0.05; Table 3).
Discussion
Strictures have been observed to develop when the muco-
sal defect extends beyond three-quarters of the esophageal
circumference in 68–92% of patients [2,5,9]. Because of
the recent trend of treating larger lesions by extensive
ESD, the number of patients with post-ESD strictures is
increasing. These strictures interfere with subsequent
management and impair quality of life. We therefore
designed a randomized, controlled trial to examine the
efficacy of endoscopic triamcinolone injection in prevent-
ing esophageal stenoses after extensive ESD, including
patients with mucosal defects encompassing the entire
circumference of the esophagus.
We found that endoscopic triamcinolone injection did
not reduce the frequency of stricture formation, butn. Some injected triamcinolone is evident in the ulcer (white arrows).
Figure 3 Esophageal stenosis assessed by esophagography. The white lines indicate the stricture caused by resection. The stricture had
substantially improved 1 month later. The left esophagogram (a) was taken 2 months after endoscopic submucosal dissection (ESD); the right
esophagogram (b) was taken 3 months after ESD.
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tient from 12.5 to 6.1, suggesting that steroid injection
may partially relieve esophageal stenoses. No steroid-
related adverse events were observed, and the perfor-
ation rate during dilatation procedures was similar in the
treated and control groups (1.0% versus 0.5%, respectively).
These results suggest that a single prophylactic dose of
steroid administered after ESD is safe and well tolerated.
The mean minimum diameter of stenotic lumens immedi-
ately before the first dilatation treatment was significantly
greater in the treated group than controls (11.0 versus
7.1 mm, respectively). The differences observed in dur-
ation of dilatation therapy were not statistically signifi-
cant. Our trial is the first to demonstrate the partial but
significant prophylactic effect of steroid injection on
stricture formation in this clinical setting.
Hanaoka and colleagues previously stated that a ran-
domized controlled trial comparing a single injection of
steroid at the time of dilatation therapy may not be ethic-
ally acceptable, as the efficacy of steroid injection therapy
is well recognized [10]. Furthermore, they stated that it
would be better justified for a future controlled trial tocompare multiple steroid injections with systemic steroids
or a different steroid injection regime. However, previous
studies – including theirs – had excluded patients with
circumferential defects from their trial, as these patients
are known to develop extremely severe strictures [8,19].
Moreover, patients with WCMDs have been reported to
require as many as 32 dilatation sessions [19], highlighting
the challenges faced by clinicians in these cases. Although
we are encountering more patients with circumferential
mucosal defects in our clinical practice, the best way of
managing them has not been determined. The results
from our post hoc analysis confirm that patients with
WCMDs are more likely to develop strictures, require
more dilatation sessions and longer duration of treat-
ment, but that they benefited most from a single
prophylactic steroid injection after ESD. In patients
with WCMDs and esophageal diameters of approxi-
mately 7 mm, prophylactic steroid treatment almost
halved the number of dilatation sessions needed and
the overall duration of treatment. This in itself is a clin-
ically important finding, not least because a reduced in-
cidence of esophageal perforation would be likely to
Figure 5 Typical endoscopic view 1 month after endoscopic submucosal dissection. Severe stenosis of the esophagus did not develop. The
right picture (a) is a magnification of the left picture (b).
Figure 4 Barium esophagography 1 month after endoscopic submucosal dissection. The yellow lines indicate the narrow lumens owing to
resection. a. Patient allocated to the control group, who developed a severe esophageal stricture that required 13 sessions of dilatation therapy.
b. Patient allocated to the treatment group, who did not require dilatation.
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Table 5 Subgroup analysis of patients with mucosal
defects involving the whole esophageal circumference







n = 5 n = 5
Frequency of stricture, n (%) 5 (100) 5 (100) 0.99
Required dilatation sessions,






Perforation by dilatations, n per
session (%)
0/52 (0) 1/111 (0.9) 0.99
Minimum diameter of stenotic






Duration for dilatations, month






Abbreviations: WCMD, whole circumferential mucosal defect; NWCMD, non-
WCMD; SD, standard deviation.
Table 3 Characteristics of dilatation procedures
undertaken in the treatment and control groups





n = 16 n = 16
Frequency of stricture, n (%) 10 (62.5) 14 (87.5) 0.22
Required dilatation sessions, n 6.1 ± 6.2 12.5 ± 10.1 0.038
mean ± SD (range) (0–17) (0–40)
Perforation by dilatations, n per
session (%)
1/97 (1.0) 1/200 (0.5) 0.55
Minimum diameter of strictured






Duration of dilatation therapy,






Abbreviation: SD, standard deviation.
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that patients are at a lower risk of esophageal perfor-
ation if they undergo fewer dilatation treatments [3],
prophylactic steroid injection might also improve pa-
tient safety, although as perforation rates are so low a
large surveillance study would be needed to detect a
difference.
Our findings also concur with those of previous stud-
ies, which showed that patients with smaller mucosal de-
fects also benefited from endoscopic steroid injections to
prevent post-ESD strictures. Our study may not have
been adequately powered to detect these smaller – but
nonetheless clinically relevant – differences in the fre-
quency of stricture formation. Our results should be fur-
ther confirmed by a large well-powered randomized
controlled trial, which should also examine whether mul-
tiple steroid injections, administered during dilatationTable 4 Post hoc analysis of characteristics of dilatation
procedures undertaken in those with mucosal defects
involving the whole circumference or less than the whole
circumference of the esophagus





n = 10 n = 22
Frequency of stricture, n (%) 10 (100) 14 (63.6) 0.035
Required dilatation sessions,






Perforation by dilatations, n per
session (%)
1/163 (0.6) 1/134 (0.7) 0.93
Minimum diameter of stenotic













Abbreviations: WCMD, whole circumferential mucosal defect; NWCMD, non-WCMD;
SD, standard deviation.treatments, might benefit those patients that go on to de-
velop esophageal stenoses.
A course of oral prednisolone has been reported to be
an effective means of preventing strictures [8]. Endo-
scopic steroid injection is preferable to oral prednisolone
in patients with diabetes mellitus, those who experience
immediate or delayed adverse events after ESD, or those
who require additional treatment for submucosal invasion.
The systemic side effects of a locally injected steroid
would likely be negligible compared with those of a sys-
temic steroid. Histopathological analysis of excised ESD
specimens showed that seven patients had tumors invad-
ing the submucosa beyond 200 μm and thus required add-
itional therapy. Oral prednisolone would likely increase
the risks associated with surgery, making it an obstacle
to immediate surgical intervention. It has previously
been reported that oral steroid therapy led to only three
patients with WCMDs requiring a mean 0.7 sessions of
dilatation therapy [8]. Thus, it remains unclear whether
locally or systemically administered steroid is superior
for patients with WCMDs. A head-to-head comparative
study may establish a standard prophylaxis for esopha-
geal stenosis caused by ESD.
The estimated sample size of 16 patients per group was
determined by a power calculation based on expected
stricture rates of 13% and 60% with and without steroid
injection, respectively, informed by previously published
data on esophageal peptic strictures [13]. These assump-
tions are now supported by another study [10], which
showed that the proportion of strictures caused by ESD
was 10% in steroid-treated patients and 66% in an his-
torical control group. Nevertheless, our study might have
been inadequately powered, as the stricture rates were
62.5% in the treatment group and 87.5% in the control
group, a likely consequence of including 10 patients
(31.3%) with circumferential mucosal defects. Furthermore,
Figure 6 Study flow chart. Patients with an expected circumferential mucosal defect involving ≥75% of the circumference of the esophagus
after ESD were eligible. Patients were excluded if they had received additional adjuvant treatments, such as surgery or chemoradiation therapy, or
if they were not adequately followed-up.
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our study were higher than in previous reports [10],
again likely a consequence of the relatively high propor-
tion of patients with circumferential lesions. The patients
in our study with NWCMDs underwent a similar mean
number of dilatation sessions to a broadly comparable
group of patients in a previous report [9]. Our study has
other limitations. First, it was an open-label design con-
ducted by a single endoscopy specialist in a single spe-
cialist center. Second, concealment was based only on
pseudo-randomization. Finally, the primary outcome meas-
ure was not significantly different between the groups, and
some of our conclusions of therapeutic benefit are based
on post hoc or subgroup analysis.Conclusion
In summary, prophylactic endoscopic steroid injection
can relieve the severity of esophageal stenoses follow-
ing extensive ESD. Future studies should attempt to
optimize steroid injection therapy to establish the best
means of preventing stricture formation in patients at
risk of developing esophageal stenosis. As it is well rec-
ognized that patients are at a lower risk of esophageal
perforation if they undergo fewer dilatation treatments
[3], prophylactic steroid injection might also improve
patient safety, although as perforation rates are so lowa large surveillance study would be needed to detect a
difference.
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